Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allergen labeling guidance

This article was originally published in The Tan Sheet

Executive Summary

"Is a major food allergen that has been unintentionally added to a food as a result of cross-contact subject to FALCPA's labeling requirements?" is a question FDA answers in the second edition of its industry guidance on the Food Allergen Labeling & Consumer Protection Act of 2004. According to the document, major food allergens that are "unintentionally" added to a food due to cross-contact are not subject to FALCPA labeling requirements. The agency first released the question-and-answer guidance in October and expects to issue new editions as more questions are posed by industry (1"The Tan Sheet" Oct. 24, 2005, p. 10). The deadline for FALCPA labeling compliance is Jan. 1...

You may also be interested in...

FDA Guidance Clarifies Labeling For Supplements Containing Food Allergens

Manufacturers of dietary supplements are required to begin labeling products that contain major food allergens on Jan. 1 in order to comply with the Food Allergen Labeling & Consumer Protection Act of 2004 (FALCPA)

New COVID Treatments Face FDA, Commercial Barriers Despite Ongoing Need

Sponsors want more endpoint clarity as current state of government pandemic response, along with scientific and regulatory hurdles, is constraining efforts to refill a shrinking COVID medicine cabinet and could create vulnerabilities for future pandemics.

China Planning To Ban Gene Editing Technology Exports

Beijing’s latest proposal to ban gene editing is viewed as a direct response to Washington’s tightening grip over the transfer of US technology to China.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts